India
Medical Technologies Sector Review
Definition and scale of sector
- Polymer/metal components,
- Electronics/electromechanical sub assemblies,
- Medical instrumentation,
- Pharmaceutical production, wholesaling
Why the sector was chosen in the West Midlands
- High rate of growth but from a low case.
- Full role played by the medical market place on regional industry is understated given the role played by industries that supply multiple markets e.g. polymers.
- Higher Education based investments demonstrate a potential for spin off activity. Opportunities for diversification. Major training region in Medical Schools and CE for the NHS.
Top of page 
Biotechnology & Pharmaceuticals Sector Report - December 2008
India is a priority high growth market for UK Trade & Investment. Recent developments in the sector in India indicate increasing business opportunities for the UK's biotechnology sector.
Following the phenomenal success of its information technology industry, India is fast emerging as an important player in the biotechnology sector in the Asia-Pacific Region. The large pool of scientific talent available at a reasonable cost, a wealth of R & D Institutions, a rich and varied bio-diversity, a flourishing pharmaceutical industry, strong IT skills and an English speaking population has placed India favourably in the global market.
A few years ago India had only 30 biotech companies worth talking about. Today about 325 companies are active in the modern biotechnology segment with combined revenues of about $2 billion. (Source: Biospectrum-Able Biotech Survey, 2008). It is expected to reach the target of $5 billion by 2010. The Indian biotech industry reported revenues of $ 2.5 billion in the just concluded FY 2007-08, reveals the 6th BioSpectrum-ABLE Biotech Industry Survey. The heady growth achieved by the industry in the last five years dropped to 20% in 2007-08 due to appreciation of the rupee and price pressures in global markets.
Source: UK Trade and Investment (UKTI)
FOR THE FULL REPORT PLEASE CLICK HERE
Healthcare and Medical Sector Report - November 2008
According to Technopak India Healthcare Trends 2008, the Indian healthcare industry is estimated to grow from current Rs 1500 billion (US$ 37.5 billion) to over Rs 3000 billion (US$ 75 billion) by 2012. At Rs 690 billion (£8 billion), private spending accounts for a significant chunk of the healthcare delivery market. The healthcare sector in India is witnessing large private sector investments in new facilities spurred by a wide demand-supply gap in healthcare delivery. Government is encouraging private participation due to constraints in public funding capability. Import incidence is high - almost 70%-80% of medical equipment for hospitals is imported. Peak import duties have been lowered to bring India in line with WTO norms.
India is now emerging as a healthcare hub in Asia due to the growing number of multi and single superspeciality tertiary care hospitals. Customer expectations for quality healthcare from private hospitals is high and most urban hospitals are striving to provide state-of-the-art care in almost all healthcare specialities. The intention of these leading private hospitals is to provide world-class international quality healthcare service at affordable rates. As a consequence, medical tourism, is a high interest area for these hospitals.
Source: UK Trade and Investment (UKTI)
FOR THE FULL REPORT PLEASE CLICK HERE
Pharmaceuticals- Market and Opportunities - A Sector Report From IBEF - July 2008
India is among the fastest growing pharmaceutical markets in the workld. The domestic pharmaceutical market recorded sales of US$ 7.3 billion in 2006 with a growth of 17.5 per cent over the previous year. Of this, retail sales were US$ 6.2 billion, while institutional sales were estimated to be around US$ 1.2 billion
Source: India Brand Equity Foundation (IBEF)
FOR FULL REPORT PLEASE CLICK HERE
Pharmaceuticals Sector Report from IBEF - April 2008
The Indian pharmaceutical sector is witnessing tremendous growth with the contract research and clinical trials businesses taking wing, and the new patent regime opening new avenues for players in the country. The country's pharmaceutical market is a US$ 7.3 billion opportunity with the domestic retail market expected to cross the US$ 10 billion mark in 2010 and be worth an estimated US$ 12-13 billion in 2012.
Source: India Brand Equity Foundation (IBEF)
FOR THE FULL REPORT PLEASE CLICK HERE
Healthcare Sector Report from IBEF - April 2008
India's healthcare sector has been growing rapidly and estimated to be worth US$ 40 billion by 2012, according to Pricewaterhouse Coopers in its report, 'Healthcare in India: Emerging market report 2007'. Revenues from the healthcare sector account for 5.2 per cent of the GDP, making it the third largest growth segment in India.
The sector's growth will be driven by the country's growing middle class, which can afford quality healthcare. Over 150 million Indians have annual incomes of more than US$ 1,000, and many who work in the business services sector earn as much as US$ 20,000 a year. Today at least 50 million Indians can afford to buy Western medicines-a market only 20 per cent smaller than that of the UK.
Source: India Brand Equity Foundation (IBEF)
FOR THE FULL REPORT PLEASE CLICK HERE
Biotechnology Sector Report from IBEF - April 2008
The Indian biotech industry - accounting for 2 per cent of the global biotech market - has the potential to develop as a key player, generating revenues worth US$ 5 billion. The domestic biotechnology industry is now a US$ 3 billion sector, registering 30 per cent growth in 2007-08 over the previous year. Furthermore, it is estimated that this sector will grow to occupy 140 million square feet by 2010, creating employment for a million by means of its products as well as its services. Significantly, an Ernst and Young survey recognises India as one of the emerging biotech leaders, ranked third in the Asia-Pacific region based on the number of biotech companies in the country.
Source: India Brand Equity Foundation (IBEF)
FOR THE FULL REPORT PLEASE CLICK HERE
Discovering new drugs - A Report from IBEF - December 2007
In the late 1990s when the life threatening Hepatitis B took an epidemic form all over India, a little known company from Hyderabad teamed up with a host of leading hospitals across the nation to develop a drug, which is today popularly known as Shanvac-B.
It happens to be the fi rst indigenously developed Hepatitis B vaccine in India, heralding the arrival of innovation in the pharmaceutical and biotechnology industry.
Source: India Brand Equity Foundation (IBEF)
FOR THE FULL REPORT PLEASE CLICK HERE
Biotech Boom - Gathering steam - A Report from IBEF - December 2007
India, which has earned a name worldwide as the most preferred destination for global Information Technology (IT) outsourcing and software services firms, is gradually making a mark in another high-tech sector - biotechnology. This sunrise sector, which has seen the entry of many new players both Indian and international, is poised to take the country to the big league with investments
flowing in from all corners. The country has traditionally done well in the pharmaceutical and drug industry. As an offshoot of the pharmaceutical industry, the biotechnology sector took shape over the last 10 years with many entrepreneurs making substantial investments in it.
According to Dr M.K. Bhan, Secretary, Department of Biotechnology, Government
of India, the industry - currently expanding at 37 per cent per annum - is growing phenomenally, and this can easily be sustained. It is projected to burgeon into a $5 billion sector by 2010.
Source: India Brand Equity Foundation (IBEF)
FOR THE FULL REPORT PLEASE CLICK HERE
Biotechnology Sector Report - July 2007
India is a priority emerging market for UK Trade & Investment. Recent developments in the sector in India indicate increasing business opportunities for the UK's biotechnology sector.
Following the phenomenal success of its information technology industry, India is fast emerging as an important player in the biotechnology sector in the Asia-Pacific Region. The large pool of scientific talent available at a reasonable cost, a wealth of R & D Institutions, a rich and varied bio-diversity, a flourishing pharmaceutical industry, strong IT skills and an English speaking population has placed India favourably in the global market.
FOR THE FULL REPORT PLEASE CLICK HERE
Source: UK Trade and Investment
Top of page 
Pharmaceutical Sector Review - July 2007
Biotechnology & Pharmaceuticals are a priority sector. From 01/01/2005, a new TRIPS-compliant IPR regime as mandated by the WTO is in place. Following the approval of the Patents (3rd Amendment) Bill by the Indian Parliament on 23 March 2005, the Indian Pharmaceuticals sector now merits an active watching brief.
The Indian Pharmaceutical sector is highly fragmented with over 20,000 registered units. The leading 250 pharmaceutical companies control 70% of the market, with the market leader Glaxo SKB having only a 5.4 % market share (CY 2004). The top 10 companies cover around 31% of the pharma market. Because of Government price controls and the fragmented nature of the market, it is an extremely competitive industry which has evolved around the opportunities presented in the regulated environment
FOR THE FULL REPORT PLEASE CLICK HERE
Pharmaceutical - Overview from IBEF - July 2007
In 2007, the Indian pharmaceutical industry looks ahead at a colourful horizon, what with contract research and clinical trials businesses taking wing, and the new patent regime opening new avenues for players in the country.
Globally the Indian pharmaceutical industry ranks 4th in terms of volume (with an 8 per cent share in global sales) and 13th in terms of value (with a share of 1 per cent in global sales). Today, the sector today is in the front rank of India's science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organised sector, the Indian pharmaceutical industry is estimated to be worth US$ 4.5 billion, growing at over 9 per cent annually.
FOR THE FULL REPORT PLEASE CLICK HERE
Source: India Brand Equity Foundation (IBEF)
Research and Development - Overview from IBEF - July 2007
India is fast emerging as the global research and development (R&D) hub of the world. In the past ten years the country has moved from a peripheral position in knowledge and technology sectors to being at the core of the continuous flow of people, ideas and technologies around the world. In 2006 alone, for example, 100 of the world's top R&D companies employed more than 15,000 scientists in India.
FOR THE FULL REPORT PLEASE CLICK HERE
Source: India Brand Equity Foundation (IBEF)
Top of page
Science and Technology - Overview from IBEF - July 2007
India is fast emerging as the global research and development (R&D) hub of the world. In the past ten years the country has moved from a peripheral position in knowledge and technology sectors to being at the core of the continuous flow of people, ideas and technologies around the world. In 2006 alone, for example, 100 of the world's top R&D companies employed more than 15,000 scientists in India.
FOR THE FULL REPORT PLEASE CLICK HERE
Source: India Brand Equity Foundation (IBEF)
Top of page | 
